OTCMKTS:CLVLY

Clinuvel Pharmaceuticals News Headlines

$22.61
-0.34 (-1.48 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.35
$22.61
50-Day Range
$20.23
$23.75
52-Week Range
$13.48
$24.13
Volume721 shs
Average Volume6,645 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Clinuvel Pharmaceuticals (OTCMKTS CLVLY) News Headlines Today

SourceHeadline
Get shorty: how Clinuvel Pharmaceuticals beat the hedgiesGet shorty: how Clinuvel Pharmaceuticals beat the hedgies
markets.businessinsider.com - April 18 at 10:42 PM
Short Interest in Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Decreases By 42.9%Short Interest in Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Decreases By 42.9%
americanbankingnews.com - April 15 at 5:14 PM
Heres Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Is An Interesting StockHere's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Is An Interesting Stock
finance.yahoo.com - April 7 at 6:34 PM
Alopecia Areata Clinical Trials Report: Pipeline Insight 2021 by DelveInsightAlopecia Areata Clinical Trials Report: Pipeline Insight 2021 by DelveInsight
in.finance.yahoo.com - March 25 at 10:49 AM
Clinuvel Pharmaceuticals Limiteds (ASX:CUV) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?Clinuvel Pharmaceuticals Limited's (ASX:CUV) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
finance.yahoo.com - February 3 at 11:57 PM
Clinuvel: Stroke And DNA Repair Unlock Large New MarketsClinuvel: Stroke And DNA Repair Unlock Large New Markets
seekingalpha.com - November 7 at 12:37 AM
CLINUVEL to Trial Innovative Drug in StrokeCLINUVEL to Trial Innovative Drug in Stroke
finance.yahoo.com - October 27 at 11:37 PM
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.